VENCLYXTO® is a selective, oral, first-in-class BCL-2 inhibitor that targets BCL-2 overexpression, which helps to restore the process of apoptosis in CLL cells

CLL=chronic lymphocytic leukaemia; 1L=first line; 2L+=second line + later lines of therapy; HR=hazard ratio; CI=confidence interval; PFS=progression-free survival; BR=bendamustine + rituximab; VEN+R=VENCLYXTO® + rituximab; BCL-2=B-cell lymphoma 2.

▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions via HPRA. Website:

Reference: 1. VENCLYXTO® Summary of Product Characteristics available at 

 IE-VNCCLL-220034:  | Date of preparation: July 2022